San Clemente-based Cameron Health Inc. will have its implantable heart defibrillator reviewed by an FDA panel on April 26, the company said.
Cameron is being bought for $150 million plus more than $1 billion in potential payments by Boston Scientific Corp. of Natick, Mass., a longtime investor. An approval by the FDA would bring the first $150 million in milestone payments included in the deal.
That deal is expected to be completed in this year’s second or third quarter.
The company makes the S-ICD, an implantable defibrillator that delivers electric shocks to people suffering from heart attacks. S-ICD is implanted subcutaneously, eliminating the need for lead wire placement inside the heart.
Cameron Chief Executive Kevin Hykes called the meeting “a significant step” toward getting approval for S-ICD. S-ICD has European approval.